National Early Music Association

VUNO's First AI-based Prospective Study Results Published in Critical Care

Retrieved on: 
Lundi, septembre 18, 2023
Blood pressure, Real, Dong-a University Hospital, Cardiac arrest, Cohort (statistics), Bed, Respiratory rate, National Early Music Association, MFDS, MEWS, Research, Multimedia, AUROC, RWD, Real World, Thermoregulation, Korean Ministry of Culture, Seoul National University Hospital, Vital signs, Patient, Patient safety, UIT, NEWS, Trial of the century, Heart rate, Medical device, Pharmaceutical industry, Nursing, Critical care, Food

VUNO announced that the multicenter clinical study paper, which confirms the clinical validity of VUNO Med®-DeepCARS™ through its initial prospective research, has been published in "Critical Care," a leading international journal in intensive care medicine.

Key Points: 
  • VUNO announced that the multicenter clinical study paper, which confirms the clinical validity of VUNO Med®-DeepCARS™ through its initial prospective research, has been published in "Critical Care," a leading international journal in intensive care medicine.
  • In the study published in Critical Care, the VUNO research team conducted a multicenter study using patient data from general wards at four tertiary medical institutions: Seoul National University Hospital, Bundang Seoul National University Hospital, Inha University Hospital, and Dong-A University Hospital, each with varying sizes, locations, and medical environments.
  • The study found that the predictive performance of VUNO Med®-DeepCARS™ had an AUROC score of 0.869, outperforming traditional methods (NEWS 0.767, MEWS 0.756).
  • In this study, VUNO Med®-DeepCARS™ displayed exceptional predictive abilities and adaptability in identifying high-risk patients, even in its first prospective research.

Biobeat's Chest Patch and Remote Patient Monitoring Platform Demonstrate Capability as a Pre-Symptomatic and Real-Time Detection and Warning Tool for Patient Deterioration

Retrieved on: 
Lundi, mars 27, 2023
Frontiers, Respiratory rate, National Early Music Association, Stroke, Booth, Early warning score, Temperature, Cardiac output, National Association Medical Staff Services, Vital signs, Patient, Physician, Risk, NEWS, Hadassah Medical Center, Artificial intelligence, Heart rate, Health, Rare-earth element, Medical device, Physiology

The article titled, "Developing a real-time detection tool and an early warning score using a continuous wearable multi-parameter monitor," was published online on March 20, 2023, in the peer-reviewed Frontiers in Physiology.

Key Points: 
  • The article titled, "Developing a real-time detection tool and an early warning score using a continuous wearable multi-parameter monitor," was published online on March 20, 2023, in the peer-reviewed Frontiers in Physiology.
  • Utilizing MPRT-WS with a remote patient monitoring platform allows physicians to receive timely alerts of pre-symptomatic and real-time deterioration and may lead to earlier intervention of high-risk patients with both acute and chronic medical conditions."
  • "Biobeat's unique Multi-Parameter Real Time Warning Score was developed using both artificial intelligence and physicians' inputs seeking more precise and frequent monitoring tools for predicting patient health deterioration.
  • Our disposable chest monitor, combined with our remote patient monitoring platform, allowed for early detection of high-risk deterioration more than 40 hours before deterioration occurred," added Prof. Arik Eisenkraft, Chief Medical Officer at Biobeat.

Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference

Retrieved on: 
Vendredi, mai 27, 2022
Knowledge, U.S. Securities and Exchange Commission, Mortality, Legislation, Plasma, Conference, Data, Monocyte, Immune system, OTCQB, National Early Music Association, Clinical trial, COVID-19, Method, Research, Brain, Alzheimer's disease, Pressure, Cell cycle, GLOBE, Company, IC50, Solution, Coronavirus, Neurodegeneration, Pharma, Biotechnology, Synthase, PCR, Apoptosis, COVID, Cancer, Severe acute respiratory syndrome coronavirus 2, Pacific Time Zone, Cancer immunotherapy, TMB-2, Patient, Ivermectin, Lymphocyte, Neuron, Personalized medicine, Technology, MERS, TBIA, CEO, Pharmaceutical industry, Medical imaging

Tollovid's 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectins published 3CL protease IC50 binding affinity.

Key Points: 
  • Tollovid's 3CL protease IC50 binding affinity is at least ten times (10x) as strong as Ivermectins published 3CL protease IC50 binding affinity.
  • Tollovid Dailys 3CL protease IC50 binding affinity is at least two and a half times (2.5x) as Ivermectin.
  • Tollovir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19.

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients

Retrieved on: 
Jeudi, janvier 27, 2022
State of emergency, CEO, SAS, Trial of the century, US FDA, COVID, Solution, Adult, NEW, CTO, Beta, Shaare Zedek Medical Center, COVID-19, Death, OTCQB, Conference, EUA, Safety, Emergency Use Authorization, National Early Music Association, SOC, Infection, US, Company, Fourth, Diagnosis, Patient, NLC, Part, GLOBE, COVID-19 deaths, Omicron, Pharmaceutical industry, Hospital, Delta

Tollovir met its primary endpoint of reducing time to clinical improvement as measured by the National Emergency Warning System 2 (NEWS2) and met several key secondary clinical endpoints, including complete reduction in COVID-19 deaths.

Key Points: 
  • Tollovir met its primary endpoint of reducing time to clinical improvement as measured by the National Emergency Warning System 2 (NEWS2) and met several key secondary clinical endpoints, including complete reduction in COVID-19 deaths.
  • The Company has now formally closed the Phase 2 clinical trial due to positive interim efficacy data.
  • Lead clinical site Shaare Zedek Medical Center now permits the use of Tollovir in hospitalized COVID-19 patients on a compassionate use basis.
  • (b) Part 2: Tollovir Clinical Trial Part 2 (TCTP2) (N=20): Tollovir formulation 2 (TLVR2) + SOC (N=11) vs.